Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Shares Sold by Oak Ridge Investments LLC

Oak Ridge Investments LLC decreased its position in shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) by 6.3% during the 4th quarter, HoldingsChannel.com reports. The institutional investor owned 32,911 shares of the biotechnology company’s stock after selling 2,226 shares during the quarter. Oak Ridge Investments LLC’s holdings in Arrowhead Pharmaceuticals were worth $619,000 at the end of the most recent quarter.

Other hedge funds have also recently bought and sold shares of the company. Values First Advisors Inc. purchased a new position in shares of Arrowhead Pharmaceuticals during the 3rd quarter worth $52,000. Mirae Asset Global Investments Co. Ltd. lifted its position in Arrowhead Pharmaceuticals by 21.3% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,496 shares of the biotechnology company’s stock worth $88,000 after buying an additional 788 shares during the period. Quantbot Technologies LP acquired a new stake in Arrowhead Pharmaceuticals in the 3rd quarter worth about $149,000. Quarry LP boosted its stake in Arrowhead Pharmaceuticals by 54.5% in the 2nd quarter. Quarry LP now owns 8,500 shares of the biotechnology company’s stock worth $221,000 after buying an additional 3,000 shares during the last quarter. Finally, State of Alaska Department of Revenue grew its holdings in Arrowhead Pharmaceuticals by 7.3% in the 3rd quarter. State of Alaska Department of Revenue now owns 14,417 shares of the biotechnology company’s stock valued at $279,000 after buying an additional 980 shares during the period. Institutional investors and hedge funds own 62.61% of the company’s stock.

Arrowhead Pharmaceuticals Trading Up 2.8 %

Shares of ARWR opened at $19.56 on Monday. Arrowhead Pharmaceuticals, Inc. has a 12 month low of $17.05 and a 12 month high of $36.72. The stock’s 50-day moving average is $20.81 and its two-hundred day moving average is $22.17. The company has a debt-to-equity ratio of 2.06, a current ratio of 6.74 and a quick ratio of 6.74. The stock has a market cap of $2.43 billion, a PE ratio of -3.90 and a beta of 0.97.

Insider Buying and Selling

In related news, insider James C. Hamilton sold 32,729 shares of Arrowhead Pharmaceuticals stock in a transaction on Monday, January 6th. The shares were sold at an average price of $19.82, for a total transaction of $648,688.78. Following the sale, the insider now owns 272,122 shares of the company’s stock, valued at $5,393,458.04. The trade was a 10.74 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CEO Christopher Richard Anzalone sold 11,520 shares of the company’s stock in a transaction dated Thursday, January 2nd. The shares were sold at an average price of $19.05, for a total transaction of $219,456.00. Following the completion of the transaction, the chief executive officer now directly owns 3,764,252 shares of the company’s stock, valued at approximately $71,709,000.60. The trade was a 0.31 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 146,473 shares of company stock valued at $2,937,847. Corporate insiders own 4.50% of the company’s stock.

Wall Street Analysts Forecast Growth

Several brokerages have recently weighed in on ARWR. Sanford C. Bernstein cut their price objective on shares of Arrowhead Pharmaceuticals from $27.00 to $24.00 and set a “market perform” rating on the stock in a report on Friday, November 29th. Royal Bank of Canada reiterated an “outperform” rating and issued a $42.00 price target on shares of Arrowhead Pharmaceuticals in a report on Thursday, September 26th. Piper Sandler lowered their price objective on shares of Arrowhead Pharmaceuticals from $62.00 to $45.00 and set an “overweight” rating for the company in a research note on Wednesday, November 27th. Chardan Capital reaffirmed a “buy” rating and issued a $60.00 target price on shares of Arrowhead Pharmaceuticals in a research report on Thursday, December 12th. Finally, HC Wainwright reissued a “buy” rating and set a $80.00 price target on shares of Arrowhead Pharmaceuticals in a research report on Friday, December 20th. One research analyst has rated the stock with a sell rating, four have given a hold rating and six have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Hold” and a consensus price target of $43.33.

About Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases.